{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=20", "query": { "intervention": "BCAA", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 15654, "total_pages": 1566, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCAA&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T19:26:10.254Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01440881", "title": "Does Nesiritide Provide Renal Protection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "Nesiritide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 37, "start_date": "2010-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-06-06", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440881" }, { "nct_id": "NCT03620019", "title": "Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage Iii", "Melanoma Stage Iv", "Melanoma", "Melanoma (Skin)", "Cutaneous Melanoma" ], "interventions": [ { "name": "Denosumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 25, "start_date": "2018-09-10", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 2, "location_summary": "Manchester, New Hampshire • Chapel Hill, North Carolina", "locations": [ { "city": "Manchester", "state": "New Hampshire" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03620019" }, { "nct_id": "NCT00002767", "title": "Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Detox-B adjuvant", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "1996-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002767" }, { "nct_id": "NCT03718767", "title": "Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Glioblastoma", "High Grade Glioma", "Low Grade Glioma", "Malignant Glioma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-03-27", "completion_date": "2026-11-30", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03718767" }, { "nct_id": "NCT00089492", "title": "A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Optimized Background ARVs", "type": "DRUG" }, { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 64, "start_date": "2004-07", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 21, "location_summary": "Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089492" }, { "nct_id": "NCT01381354", "title": "Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Progressive exercise", "type": "OTHER" }, { "name": "Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV", "type": "DEVICE" }, { "name": "Modified paleolithic diet", "type": "OTHER" }, { "name": "Omega 3 fatty acids", "type": "DIETARY_SUPPLEMENT" }, { "name": "Full Spectrum vitamin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Essential - hydroxytyrosol", "type": "DIETARY_SUPPLEMENT" }, { "name": "Maltodextrin fiber supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Mineral boost (magnesium)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Niacinamide", "type": "DIETARY_SUPPLEMENT" }, { "name": "Methyl B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Taurine", "type": "DIETARY_SUPPLEMENT" }, { "name": "creatine", "type": "DIETARY_SUPPLEMENT" }, { "name": "thiamine", "type": "DIETARY_SUPPLEMENT" }, { "name": "riboflavin", "type": "DIETARY_SUPPLEMENT" }, { "name": "N acetylcysteine", "type": "DIETARY_SUPPLEMENT" }, { "name": "alpha lipoic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "L acetyl carnitine", "type": "DIETARY_SUPPLEMENT" }, { "name": "methyl folate", "type": "DIETARY_SUPPLEMENT" }, { "name": "coenzyme Q", "type": "DIETARY_SUPPLEMENT" }, { "name": "meditation", "type": "BEHAVIORAL" }, { "name": "self massage", "type": "BEHAVIORAL" }, { "name": "learning", "type": "BEHAVIORAL" }, { "name": "Coconut oil", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "OTHER", "DEVICE", "DIETARY_SUPPLEMENT", "BEHAVIORAL" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2010-10", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381354" }, { "nct_id": "NCT00214266", "title": "A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Campath 1H®, Rituximab, mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2005-01", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00214266" }, { "nct_id": "NCT00450801", "title": "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2004-04", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2015-11-10", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450801" }, { "nct_id": "NCT00946712", "title": "S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Large Cell Lung Carcinoma", "Recurrent Lung Adenocarcinoma", "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Large Cell Lung Carcinoma", "Stage IV Lung Adenocarcinoma", "Stage IV Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1333, "start_date": "2009-07-15", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 797, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946712" }, { "nct_id": "NCT00641030", "title": "Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "120 Years", "sex": "ALL", "summary": "1 Year to 120 Years" }, "enrollment_count": 20, "start_date": "2007-07-27", "completion_date": "2011-01-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-27T19:26:10.254Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641030" } ] }